AVTE NASDAQ
Aerovate Therapeutics, Inc.
1W: -3.2%
1M: +5.9%
3M: +4.3%
1Y: -87.4%
3Y: -82.0%
$2.68
Last traded 2025-04-28 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$77.7M
52W Range2.6296-884.975
Volume981,795
Avg Volume7,993
Beta0.95
Dividend$2.40
Analyst Ratings
Company Info
CEOTimothy P. Noyes
Employees4
SectorHealthcare
IndustryBiotechnology
IPO Date2021-06-30
Websitejadebiosciences.com
930 Winter Street
Waltham, MA 02116
US
Waltham, MA 02116
US
617 443 2400
About Aerovate Therapeutics, Inc.
Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise focused on innovating therapies to enhance the well-being of patients afflicted with rare cardiopulmonary illnesses across the United States. The company's principal effort involves advancing AV-101, an inhaled dry powder variant of imatinib, which is currently undergoing a Phase 2b/Phase 3 clinical study for the management of pulmonary arterial hypertension. Established in 2018, Aerovate Therapeutics, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Dake Benjamin T | M-Exempt | 1,507 | $1.74 | 2024-08-01 |
| Dake Benjamin T | M-Exempt | 1,507 | $1.74 | 2024-08-01 |
| Dake Benjamin T | M-Exempt | 11,454 | $1.74 | 2024-07-31 |
| Dake Benjamin T | M-Exempt | 10,548 | $1.74 | 2024-07-31 |
| RA CAPITAL MANAGEMEN | P-Purchase | 928,110 | $1.67 | 2024-06-17 |